Skip to main content

Clinical Trials Using Oxaliplatin

Review the clinical trials studying oxaliplatin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 139

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Onvansertib in Combination with NALIRIFOX for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients with Soft Tissue Sarcoma, Bone Sarcoma, or Colorectal Cancer Metastatic to the Lungs
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Erlotinib, Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Basal-Like Pancreatic Cancer, PANGEA Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
Status: Active
Location: 2 locations
Chemotherapy with Radiation for the Treatment of Rectal Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Adaptive Radiation Therapy Boost for the Treatment of Rectal Cancer, The ARBOR Trial
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Zunsemetinib with mFOLFIRINOX for the Treatment of Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neoadjuvant Chemotherapy Combined with Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, SMART TNT Study
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Aldesleukin in Combination with Nivolumab and Standard Chemotherapy for the Treatment of Gastric Cancer with Peritoneal Metastasis, CONTROL Study
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
9-ING-41 and Retifanlimab with FOLFIRINOX for the Treatment of Advanced Recurrent or Metastatic Pancreatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Intraperitoneal Paclitaxel with NALIRIFOX for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Response-Guided Neoadjuvant Treatment Approach for Treating Stage Ib-III Stomach or Gastroesophageal Junction Cancer, RANT-GC Trial
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy and Bevacizumab with the NovoTTF-100L/ NovoTTF-200T System in Treating Patients with Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Adaptive, Individualized Dose Escalation of the FOX Regimen for the Treatment of Metastatic or Locally Advanced/Inoperable Gastrointestinal Cancer
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Circulating Tumor DNA for Risk Determination and Treatment Selection in Patients with Carcinomatosis from Colorectal or Appendiceal Adenocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov